Sorafenib-resistant PDGFR mutants

Stable Identifier
R-HSA-9674404
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Sorafenib is a type II tyrosine kinase inhibitor that is approved for use in hepatocellular and renal cell carcinoma, and that is often used as a second-line treatment for imatinib-resistant tumors. Despite its initial efficacy, resistance to sorafenib often develops (reviewed in Molina-Ruiz et al, 2017).

Literature References
PubMed ID Title Journal Year
29431086 Antitumoral Activity of Sorafenib in Hepatocellular Carcinoma: Effects on Cell Survival and Death Pathways, Cell Metabolism Reprogramming, and Nitrosative and Oxidative Stress

Molina-Ruiz, FJ, Gonzalez, R, Rodriguez-Hernandez, MA, Navarro-Villaran, E, Padillo, FJ, Muntané, J

Crit Rev Oncog 2016
22089421 Gastrointestinal stromal tumours: origin and molecular oncology

Corless, CL, Barnett, CM, Heinrich, MC

Nat. Rev. Cancer 2011
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!